Journal
CURRENT DRUG METABOLISM
Volume 21, Issue 5, Pages 357-367Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389200221666200514131721
Keywords
Anticancer drug; pharmacokinetics; absorption; excretion; metabolism; surufatinib
Funding
- Hutchison MediPharma Ltd.
- National Key New Drug Creation Special Programs [2017ZX09304021]
- Jiangsu Provincial Medical Youth Talent [QNRC2016714]
- National Natural Science Foundation of China [81773820]
- Jiangsu Provincial Medical Talent [ZDRCA2016048]
- Suzhou Key Laboratory of Drug Clinical Research and Personalized Medicine [SZS201719]
Ask authors/readers for more resources
Background: Surufatinib is a potent small-molecule tyrosine kinase inhibitor and exhibited significant efficacy in the treatment of neuroendocrine tumors in clinical trials. Objective: The absorption, metabolism and excretion of surufatinib were investigated in rats and human volunteers following a single oral dose of [C-14] surufatinib. Methods: The radioactivity was measured in plasma, urine, feces and bile by liquid scintillation counting, and the metabolites were characterized by liquid chromatography coupled to mass spectrometry. Results: Surufatinib was orally absorbed similarly in rats and human volunteers, with the median T-max of 4 hours post-dose. The estimated t(1/2) appeared longer in humans than in rats (mean t(1/2): 3.12 hour for male rats, 6.48 hours for female rats and 23.3 hours for male human volunteers). The excretion of surufatinib was almost complete in rats and human volunteers in the studies, with the total radioactivity recovery of >90% of the dose. Similarly, in rats and humans, fecal excretion predominated (approximately 87% of the dose recovered in feces and only 5% in urine). The parent drug was the major radioactive component detected in the plasma extracts of rats and humans, and no single circulating metabolite accounted for >10% of the total radioactivity. Unchanged drug was a minor radioactive component in the excreta of rats and humans. Conclusion: Fecal excretion was the predominant way for the elimination of surufatinib and its metabolites in rats and humans. No disproportionate circulating metabolite was observed in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available